New website is here!
Create an account to use the new features. Feel free to leave us feedback, constructive criticism welcome!

Anteris Technologies Ltd (avr) Logo

Anteris Technologies Ltd (AVR)

___:___ · AUD
0.00
0.00
(0.00)
VOLUME
DIV YIELD
PE RATIO
1 YR RETURN
52 WEEK RANGE

AVR Chart

AVR's Principal Activity is the sale, distribution, maintenance and implementation of infusion solutions to major hospitals and health facilities in Australia and New Zealand; The manufacturing, sale and distribution of proprietary ADAPT regenerative tissue products globally; and Continued research and development of regenerative medicine and immunotherapies.

Share Price Activity

Last (Price)
Change 0.00 (0.00)
Bid / Ask -
Volume
Volume (4w avg)
Turnover
Open
Day Range -
VWAP
Prev Close
Last Trade

Performance

1 Week
1 Month
2021 YTD
1 Year
vs Sector (1yr) -35.40%
vs ASX 200 (1yr) -40.54%

Size

Market Capitalisation
ASX Rank 1508 of 2,466
Sector Rank 132 of 177

Key Information

Shares Issued
Sector Healthcare
Similar Companies RNO / GMV / PAA
EPS -$0.04
DPS $0.00
NTA per share $1.10

Broker Consensus

AVR is not covered by a major broker, or data from most recent compilation was omitted due to not meeting QA guidelines.

Announcements

Date Heading Pages File Size Time

Company Overview

Anteris Technologies Ltd (AVR, formerly Admedus Ltd) is a structural heart company delivering clinically superior solutions that help healthcare professionals create life-changing outcomes for patients. Its focus is on investing in and developing next generation technologies with world class partners and acquiring strategic assets to grow product and service offerings.

Incorporation Details

Incorporated bioMD Limited was incorporated in June 1999 in Western Australia. Code changed to Allied Healthcare Group Ltd (AHZ) on 30/06/2011

Corporate Details

Head Office Toowong QLD 4066
Website www.anteristech.com
Registry Computershare
Auditor HLB Mann Judd
Date Listed 24 Mar 2004

Upcoming Calendar

Date Event
26/02/2021 Report (Prelim)
08/04/2021 Report (Annual)
19/08/2021 Report (Interim)

Dividend History

Ex-Date Amount Franking Gross Type Payable
No dividends paid.

See Upcoming Dividends for all ASX companies.

Directors & Management

Directors & Management

Name Title Since Bio
Dr Yanheng Wu Non-Executive Director Dec 2018 Director Bio icon

Dr Yanheng Wu

Non-Executive Director

Dr Wu is the President and Vice chair of Constellation International (Group) Holdings Ltd. In 2016, he established Guangzhou Hearty-Care Biotechnology Ltd., a medical technology company that is now owned by Constellation International (Group) Holdings Ltd. He holds multiple biomedical patents.

Mr Stephen (Steve) Denaro Company Secretary, Non-Executive Director Oct 2018 Director Bio icon

Mr Stephen (Steve) Denaro

Company Secretary, Non-Executive Director

Mr Denaro has more than 30 years of senior level and Board level experience across publicly listed companies; serving as Chief Financial Officer, Company Secretary and Director. He has experience in managing compliance with finance and accounting regulatory requirements. He has managed investment acquisitions and subsequent funding (domestic and international). He also chairs the Risk Management Committee.

Dr Wenyi Gu Non-Executive Director Oct 2018 Director Bio icon

Dr Wenyi Gu

Non-Executive Director

Dr Gu works as Research Fellow for the Australian Institute for Bioengineering and Nanotechnology at The University of Queensland (UQ), where he began his post-doctoral work in 2001. He was supported by the National Health and Medical Research Council (NHMRC) to work at Harvard Medical School, Harvard University as a visiting research fellow. Before he was into nano medicine (focusing on drug delivery and cancer therapy), he worked on RNAi-based gene therapy for several years at Translation Research Institute (TRI). His research has been published in respected industry journals such as Nature Communications, Ad. Materials, ACS Nano and PNAS USA. He is a Nominee Non-Executive Director for major shareholder, Star Bright Holding Ltd. He is also a member of Risk Management Committee.

Mr Mathew James Ratty Executive Director, Chief Executive Officer, Managing Director Dec 2017 Director Bio icon

Mr Mathew James Ratty

Executive Director, Chief Executive Officer, Managing Director

Mr Ratty is an experienced investor in Australian and US equity and debt markets. He has experience across capital raising advice, seed investment negotiation, corporate strategy and financial modelling. He is the co-founder of MC Management Group Pty Ltd. At MC Management Group Pty Ltd Mr Ratty holds the position of Head of Investment and is responsible for negotiating deal structures and asset pricing for companies in the healthcare, financial and technology space. Prior to this, Mr Ratty was a director and analyst at property development and equity company, Gladstone Bridge.

Mr Robert (Rob) E.T Towner Non-Executive Director Feb 2017 Director Bio icon

Mr Robert (Rob) E.T Towner

Non-Executive Director

Mr Towner has over 20 years of experience in the corporate advisory and finance sectors. He was appointed Managing Director & CEO of Triangle Energy (Global) Ltd in July 2014 and managed the Company's transition from operating Indonesian based assets to establishing a portfolio of Australian oil and gas projects, including the producing Cliff Head Oil Field and associated infrastructure in the Perth Basin, Western Australia. Rob has experience in the oil and gas sector and has been involved in a number of capital raisings for projects throughout Australia, Canada, Asia and the USA since the early 1990's. Rob represents Triangle's 32.68% interest on the board of State Gas Ltd as a non-executive Director.

Mr Wayne Paterson Managing Director, Chief Executive Officer Feb 2016 Director Bio icon

Mr Wayne Paterson

Managing Director, Chief Executive Officer

Mr Paterson has held senior positions in multi national pharmaceutical companies during the past 25 years. Throughout his career, he has been responsible for building and managing multi-billion dollar businesses throughout the world, including mergers, integrations, acquisitions and major restructures as President and CEO. From 2005 to 2013 he held senior positions at Merck Kgaa, most recently as President of Europe, Canada and Australia. Prior to this, he was President of Emerging Markets, President of Japan and Global Head of Cardiovascular Medicine. Between 1999 and 2005, he served at Roche Pharmaceuticals where he was most recently Head of Pharmaceuticals in Roche's South Korean operation. He also served as Head of Commercial Operations for Roche China based in Shanghai. He held as a director in Cepheid Inc from April 2015 to November 2016.

Mr John Seaberg Non-Executive Director, Non-Executive Chairman Oct 2014 Director Bio icon

Mr John Seaberg

Non-Executive Director, Non-Executive Chairman

Mr Seaberg served as Chairman of the Board of Synovis Inc, a Minneapolis based manufacturer of various medical devices and bio scaffold tissue products from 2008 until its sale to Baxter in 2012. From 2007 until 2014 he was Founder, Chairman and CEO of NeoChord Inc., a venture capital backed company commercializing technology developed at the Mayo Clinic for the repair of the mitral valve via minimally invasive techniques. From 1996 to 2006, he served at Guidant Corp (subsequently acquired by Boston Scientific Corp) where he served in various executive level positions including Director of Bradycardia Marketing for Cardiac Rhythm Management, Vice President of Sales for Cardiac Surgery and Vice President of Sales for Cardiac Rhythm Management. In 1991, he was co-founder of ACIST Medical and served as its first President and CEO. He is also a member of Member of the Risk Management Committee.

Mr Robert Norman Scott Lead, Non-Executive Director Mar 2013 Director Bio icon

Mr Robert Norman Scott

Lead, Non-Executive Director

Mr Scott has over 35 years' experience as a corporate advisor. Mr. Scott is a former senior partner of the international accounting firms of KPMG and Arthur Andersen. Mr. Scott is the Chair of the Risk and Disclosure Committee.

Mr Peter R Turvey Non-Executive Director, Non-Executive Deputy Chairman Mar 2012 Director Bio icon

Mr Peter R Turvey

Non-Executive Director, Non-Executive Deputy Chairman

Mr Turvey has had more than 30 years of experience in the biotech/pharmaceutical industry having been former Executive Vice President Licensing, Group General Counsel and Company Secretary of global biopharmaceutical company CSL, retiring in 2011. He was also part of the protection and licensing of CSL's intellectual property and for risk management within CSL, which included management of the internal audit function, reporting to the Audit & Risk Management Committee of the Board as well as being the Chairman of the Corporate Risk Management Committee. In his senior executive role at CSL, he was part of CSL's M&A and equity capital raising activities over a 15 year period, including during the time of the float of CSL as a publicly listed company. In addition to his expertise in corporate finance, audit and risk management, Mr Turvey has experience in commercialisation and pharmaceutical product development. Mr Turvey is currently Chairman of ImmVirX Pty Ltd, a NonExecutive Director of Cell Therapies Pty Ltd (a subsidiary of the Peter MacCallum Cancer Centre), and a director of Agriculture Victoria Services Pty Ltd and Phytogene Pty Ltd. He is Chairman of the Risk Committee.

Ms Catherine (Kate) Mary Costello Non-Executive Director, Non-Executive Chairman Aug 2005 Director Bio icon

Ms Catherine (Kate) Mary Costello

Non-Executive Director, Non-Executive Chairman

Ms Costello is a professional, Non-executive Director having sold her consultancy, Governance Matters, in 2017. Prior to establishing Governance Matters she worked in management at a commercial law firm and is an expert in strategy, governance and commercial law. Kate's board experience has spanned commercial, statutory and not-for-profit entities across diverse sectors: banking and finance; engineering; defence; biotech; entertainment; gaming; software; education; employment; housing and accommodation and professional services. She is a Director of Whittles Management Services Pty Ltd, a trustee of Adelaide Workers' Homes and a member of the Diocesan Finance Council of the Adelaide Archdiocese of the Catholic Church. She is an expert in corporate governance, board performance and strategy.

Lishan Zhang N/A
Simon Buckingham N/A
Christopher Catlow N/A
William Rowley N/A
Lee Rodne N/A
Michael Bennett N/A

Director Transactions

AVR directors must report any change in shareholding to the ASX within 5 business days.

See Director Transactions for all ASX companies.

Date Director Type Amount Price Value Notes
10/12/20 Wayne Paterson Expiry 1,000 $3.80 $3,800 Options expired
10/12/20 John Seaberg Expiry 1,000 $3.80 $3,800 Options expired
20/03/20 Stephen (Steve) Denaro Issued 25,000 $3.50 $87,500 Issue of options
20/03/20 Wayne Paterson Issued 350,000 $3.50 $1,225,000 Issue of options
20/03/20 John Seaberg Issued 60,000 $3.50 $210,000 Issue of options
20/03/20 Stephen (Steve) Denaro Issued 25,000 $3.50 $87,500 Issue of options
20/03/20 Wayne Paterson Issued 350,000 $3.50 $1,225,000 Issue of options
20/03/20 John Seaberg Issued 60,000 $3.50 $210,000 Issue of options
18/12/18 Wayne Paterson Issued 700,000 $0.061 $42,700 Rights issue
18/12/18 John Seaberg Issued 700,000 $0.08 $56,000 Rights issue
18/12/18 Yanheng Wu Issued 47,178,461 $0.08 $3,774,278 Rights issue
18/12/18 Lishan Zhang Issued 62,897,248 $0.061 $3,836,732 Rights issue
18/12/18 Wayne Paterson Issued 700,000 $0.08 $56,000 Rights issue
18/12/18 Yanheng Wu Issued 47,178,461 $0.061 $2,877,886 Rights issue
18/12/18 Lishan Zhang Issued 62,897,248 $0.08 $5,031,781 Rights issue
18/12/18 John Seaberg Issued 700,000 $0.061 $42,700 Rights issue
28/06/18 Simon Buckingham Issued 333,333 $0.30 $100,000 Placement
28/06/18 Wayne Paterson Issued 166,667 $0.30 $50,000 Placement
28/06/18 John Seaberg Issued 166,667 $0.30 $50,000 Placement
08/06/18 Catherine (Kate) Costello Issued 418,817 $0.124 $51,869 Issue of options
08/06/18 Wayne Paterson Issued 1,435,630 $0.124 $177,798 Issue of options

Director Interests

The current holdings of AVR directors.

Director Last Notice Direct Shares Indirect Shares Options Convertibles
Wayne Paterson 10/12/2020 916,667 N/A 403,248 N/A
John Seaberg 10/12/2020 885,703 N/A 67,000 N/A
Stephen (Steve) Denaro 20/03/2020 0 N/A 25,000 N/A
Wenyi Gu N/A N/A N/A N/A N/A

Shareholder Info

Top 20 Shareholders About the Data

Data supplied by Morningstar and accurate on Mar 27, 2020.

It's not possible to publish a real-time Top 20 Shareholder list. Companies are not obliged to report this data (with the exception of Substantial Shareholders above 5%). If a company chooses to publish the data, it's usually once a year in their Annual Report.

All data is manually compiled so there might be a delay between the Annual Report being published and the data appearing on Market Index (<7 days for ASX 300 and up to 30 days for micro-caps).

Name Shares Capital
Constellation Intl Holdings Limited 730,192 12.35%
HSBC Custody Nominees (Australia) Limited A/C 2 652,219 11.04%
Constellation Immunotherapy Limited 402,093 6.80%
National Nominees Limited <Db A/C> 373,228 6.31%
HSBC Custody Nominees (Australia) Limited Gsco Eca 290,293 4.91%
Star Bright Holding Limited 173,680 2.94%
Merrill Lynch (Australia) Nominees Pty Limited <Mlpro A/C> 169,733 2.87%
J P Morgan Nominees Australia Pty Limited 87,768 1.48%
Citicorp Nominees Pty Limited 84,369 1.43%
Mr Patrick Chew 73,670 1.25%
Dr Abdul Ahad Khan 36,895 0.62%
Mr Daniel Bernard Clough 33,584 0.57%
Through2 Investments Pty Ltd <Through2 Super Fund A/C> 33,000 0.56%
Mr Roger Anthony Pierce 32,673 0.55%
Bulldog Shale Pty Ltd <Bulldog Shale S Fund A/C> 30,000 0.51%
Carron Services Limited 28,572 0.48%
Mr Joseph John Doyle and Mrs Cheryl Anne Doyle 23,527 0.40%
Mr Athanasios Farmakis 23,000 0.39%
Zcsf Nominees Pty Ltd <Zoeller Superfund A/C> 20,505 0.35%
Mr Dale Anthony Reed 20,000 0.34%
Appwam Pty Ltd 20,000 0.34%
Mrs Janet Louise Bowtell and Mr Gary Owen Bowtell <Bowtell Super Fund A/C> 20,000 0.34%

Shareholder Distribution

Holding Size 1 - 1,000 1,001 - 5,000 5,001 - 10,000 10,001 - 100,000 100,001+ Total
No. of Shareholders 5,647 411 72 41 7 6,178

Substantial Shareholders

A substantial shareholder is a person or entity that owns 5% or more of the voting shares in a company. Shares can be held under multiple names so the Substantial Shareholders list differs from the Top 20 Shareholders list.

Name Last Notice Total Shares Shares Held (%)
Sio Partners LP 27/03/2020 1,311,079 22.18
Mercer Street Global Opportunity Fund LLC 20/01/2021 341,545 5.20
Star Bright Holding Limited 14/07/2020 730,192 12.35

Shareholders Buying

Date Name Bought Previous % New %
20-01-21 Mercer Street Global Opportunity Fund LLC -- -- 5.20
14-07-20 Constellation Immunotherapy Limited -- -- 5.53

Shareholders Selling

Date Name Sold Previous % New %
20-07-20 Constellation Immunotherapy Limited -- 5.53 --
14-07-20 Star Bright Holding Limited 546,963 21.61 12.3
18-06-20 Star Bright Holding Limited 132,176,280 22.62 21.6

Historical Data

Share Price History

Date Close Change %Chg Open High Low Volume Turnover

Historical Data

Year Closing Price Last Trade
2020 $4.90 30 June
Page Icon
AVR Historical Price Data (CSV)
Up to 20 years of EOD share price history
Lock Icon
You must be logged in to access this feature. Please sign up for free or login.
Market Index, ASX and Morningstar Logos

All data on this page is supplied by the ASX, Morningstar and Market Index. Read the disclaimer.